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cultured with DAPT exhibited a less pronounced fall of mRNA
and protein level of type II collagen and aggrecan, and a minor
increase of type I collagen mRNA. In order to further confirm the
participation of Notch1 in the dedifferentiating process of iMACs,
we transiently transfected the cultured cells with an expression
plasmid encoding a constitutively active form of Notch 1 receptor
(DE form) which is constitutively cleaved by the γ-secretase,
releasing the transcriptionally active nuclear form of Notch, ICv.
After 24 hours of transfection we observed a strong diminution of
type II collagen amount, detected by western blot, whereas the
Notch1 full length construction as well as the empty vector had
no detectable effect. This diminution was abolished in presence
of the γ-secretase inhibitor DAPT (2,3μM).
Conclusions: These data show that the Notch pathway is critical
in the dedifferentiation process of articular chondrocytes. We
suggest that modulating the Notch pathway could be a novel
approach in the treatment of OA.
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Purpose: Alterations in chondrocyte differentiation, including
chondrocyte hypertrophy, promote dysregulated articular carti-
lage matrix repair and tissue failure in aging and osteoarthritis
(OA). IL-8 and TNFα induce chondrocyte hypertrophy, dependent
on both release of ligands of receptor for advanced glycation
endproducts (RAGE) and expression of the protein crosslinking
enzyme transglutaminase 2 (TG2). S100/calgranulins are proto-
typical RAGE ligands. S100A11 release, markedly upregulated in
human OA chondrocytes in situ, is induced by IL-8 and TNFα in
vitro. S100A11 is crosslinked by TG2-catalyzed transamidation to
change conformation and multimerize, with potential for altered
signaling through the calgranulin receptors RAGE and CD36.
Hence, we tested the hypothesis that TG2 post-translationally
modifies S100A11 released by chondrocytes, triggering articular
chondrocyte maturation to hypertrophy.
Methods: We studied not only human articular chondrocytes
but also RAGE knockout, TG2 knockout, and congenic wild
type mouse femoral head articular cartilage explants. Adapting
methods of Salvat et al (OA Cartilage 13:243, 2005), we also
isolated immature murine articular chondrocytes confirmed to
uniquely express type II collagen and aggrecan. We generated
TG2 transamidation site point mutants (K3L, Q102N, and both) of
human S100A11 and as a control a K52R S100A11 site mutant.
We also made single and double mutants for human TG2 GTP
binding (K173L) and transamidation catalytic (C277G) sites.
Results: RAGE knockout chondrocytes and femoral head carti-
lage explants retained the capacity for IL-1-induced NO and GAG
release, ADAMts4 and 5 expression, and decreased proteogly-
cans (PG) synthesis. In contrast, we confirmed that IL-8 and
TNFα required RAGE to induce type X collagen in chondrocytes
(J. Immunol. 175:12, 2005), and TNFα-induced GAG release
was blunted in RAGE knockout cartilage explants. Nanomolar
S100A11 failed to induce type X collagen and other markers
of chondrocyte hypertrophy in both RAGE and TG2 knockout
mouse chondrocytes and in human chondrocytes in which TG2
was knocked down by RNAi. Conversely, nanomolar exogenous
TG2 markedly accelerated chondrocyte hypertrophy in response
to recombinant S100A11, an effect abrogated by the TG2 C277G
but not K173L mutation. The K3R/Q102N S100A11 mutation
but not the K52R S100A11 mutation removed the capacity of
S100A11 to induce chondrocyte hypertrophy. Wild type but not
K3R/Q102N mutant S100A11 stimulated a 69% increase in GAG
release in wild type mouse femoral head cartilage explants
(P<0.05). Wild type S100A11 also failed to induce GAG release
in either RAGE or TG2 knockout explants. Last, wild type but
not K3R/Q102N mutant S100A11 induced decreased PG syn-
thesis in cultured chondrocytes. In contrast, wild type S100A11
induced 80-120% increase in PG synthesis in TG2 knockout
chondrocytes compared to wild type (P<0.05).
Conclusions: TG2-catalyzed transamidation of K3 and Q102
residues transforms latent S100A11 calgranulin to a conforma-
tional state in which S100A11 induces hypertrophic differenti-
ation, GAG release, and decreased PG synthesis. Conversely,
S100A11 fails to do so in the absence of RAGE or TG2(or the
capacity to be transamidated and crosslinked by TG2), condi-
tions under which S100A11 actually is anabolic as evidenced
by PG synthesis. Our results suggest a novel model by which
chondrocyte hypertrophy and a matrix catabolic program in OA
cartilage are switched on by pericellular TG2-induced conforma-
tional change in cytokine-inducible secreted calgranulins.
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Purpose: The aim of this study was to determine whether intra-
articularly delivered TIMP-3 protects cartilage in a rat meniscal
tear model of osteoarthritis. TIMP-3, a protein of 24 kD that
binds to extracellular matrix, is a potent inhibitor of the metal-
loproteases that degrade aggrecan and type II collagen. It also
inhibits TACE, the major enzyme that generates the soluble form
of TNF. The protein consists of two discrete domains, and the
inhibitory function is carried out by the N-domain. The N-domain
has been shown to block IL-1-driven glycosaminoglycan (GAG)
release in cartilage explants.
Methods: Two forms of TIMP-3 were produced: His-tagged full-
length was made in CHO cells, while the N-domain was made in
E. coli and refolded. Both forms were tested for efficacy against
metalloproteases in vitro, against TNF release in cell culture, and
against GAG release in bovine nasal cartilage explants. They
were then tested in a model of osteoarthritis in which symptoms
are induced by cutting the meniscus in knees of male Lewis rats.
The test proteins, rat serum albumin, or vehicle were injected
intra-articularly every other day for 3 weeks, starting one day
prior to the surgery. The volume injected was 60 ul; the amount
of protein was 100 ug for full-length TIMP-3 and albumin, 62 ug
for the N-domain. At the end of the 3-weeks, joints were fixed,
embedded, sectioned and stained, and then analysis was carried
out for GAG content, cartilage width at various sites, osteophytes
and bone lesions.
Results: Full-length TIMP-3 inhibited MMP-13 by about 80%
at a ratio of 1:1, while the N-domain did so only at a 20-fold
higher concentration. However, the two forms were similarly
effective against other metalloproteases tested, and in blocking
TNF release from a mouse monocytic cell line (IC50 about 75
nM in the cell assay). Both forms blocked IL-1-induced GAG
release from bovine nasal cartilage, with IC50s of about 100
nM and 30 nM for full-length and N-domain, respectively. In the
rat meniscal tear model, both forms reduced symptoms, with the
most dramatic effects seen in the rats that received the full-length
protein: 94% reduction in significant tibial cartilage degeneration
width, 53% reduction in medial tibial osteophyte score, 67%
reduction in bone score, and 57% reduction in total joint score.
